72 BLA 125742 0 08 13 2021 Telecon Labeling via FAX e

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

2

Document text

From:  Smith, Michael (CBER)  
Sent:  Friday, August 13, 2021 6:22 PM  
To: Aghajani Memar, Neda <[email protected]>  
Cc: Naik, Ramachandra <[email protected]>; Gottschalk, Laura 
<[email protected]>; Harkins Tull, Elisa <[email protected]>; Devlin, Carmel M 
<[email protected]>  
Subject:  STN 125742.0: 3rd set of PI labeling comments  
 
Neda, 
 
We have the attached 3rd set of comments on the Package Insert (PI). Please e -
mail us the further revised PI (both Word tracked- changes and Word annotated) 
by noon Monday, August 16, 2021, and follow up with a submission to the BLA.   Please note that w e will have additional comments for you on the PI next 
week.  
  
Regards,  
 
Mike  
 
- Please confirm receipt of this e -mail  and let us know if you have any 
questions.  
 
 
 Mike Smith, Ph.D.  
Captain, USPHS  
 Senior Regulatory Review Officer  
Food and Drug Administration  
Center for Biologics Evaluation & Research  
Office of Vaccines Research & Review  
Division of Vaccines and Related Products Applications Tel: 301- 796-2640 
[email protected]  
 
 
         
 
 
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS 
ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW.  If you are not the addressee, or a 
person authorized to deliver the document to the addressee, you are hereby 
FDA-CBER-2021-5683-1024793
notified that any review, disclosure, dissemination, copying, or other action 
based on the content of this communication is not authorized.   If you have 
received this document in error, please immediately notify  the sender 
immediately by e- mail or phone.  
 
 
 
 
FDA-CBER-2021-5683-1024794